A review of current and future treatment strategies for malignant astrocytomas in adults

Strahlentherapie und Onkologie

Volumn 176, Issue 6, 2000, Pages 251-258

  Nieder, Carsten ^a   Nestle, Ursula ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Anaplastic astrocytoma; Glioblastoma multiforme; Malignant glioma; Prognostic factors; Therapy

Indexed keywords

CARMUSTINE; CLADRIBINE; EFLORNITHINE; GLYCOPROTEIN P; HYDROXYUREA; IRINOTECAN; LEFLUNOMIDE; MATRIX METALLOPROTEINASE INHIBITOR; PACLITAXEL; PRINOMASTAT; PROCARBAZINE; PROTAMINE; PROTEIN KINASE INHIBITOR; TEMOZOLOMIDE; TENIPOSIDE; THALIDOMIDE; TOPOTECAN; VALPROIC ACID; VASCULOTROPIN;

ADULT; ASTROCYTOMA; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL TRIAL; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; META ANALYSIS; PROGNOSIS; QUALITY OF LIFE; REVIEW; SURVIVAL RATE;

EID: 0034043295     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000660050006     Document Type: Review

References (81)

1. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
2. Alavi JB, Eck SL. Gene therapy for malignant gliomas. Hematol Oncol Clin N Am 1998;12:617-29.
3. Arrieta O, Guevara P, Reyes S, et al. Protamine inhibits angiogenesis and growth of C6 rat glioma; a synergistic effect when combined with carmustine. Eur J Cancer 1998;34:2101-6.
4. Barker FG, Israel MA. Molecular genetics. In: Berger MS, Wilson CB, eds. The gliomas. Philadelphia: Saunders, 1999:39-51.
5. Belanich M, Pastor M, Randall T, et al. Retrospective study of the correlation between DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 1996;56:783-8.
6. Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. Br J Cancer 1991;64:769-74.
7. Bower M, Newlands ES, Bleehen NM, et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 1997;40:484-8.
8. Brada M, Thomas G, Elyan S, et al. Improving the acceptability of high-dose radiotherapy by reducing the duration of treatment: accelerated radiotherapy in high-grade glioma. Br J Cancer 1995;71:1330-4.
9. Brada M, Thomas DG, Bleehen NM, et al. Medical Research Council (MRC) randomised trial of adjuvant chemotherapy in high-grade glioma. Proc Am Soc Clin Oncol 1998;17:1543. abstract.
10. Brandes AA, Rigon A, Zampieri P, et al. Carboplatin and teniposide concurrent with radiotherapy in patients with glioblastoma multiforme. Cancer 1998;82:355-61.
11. Bredel M, Pollack IF, Freund JM, et al. Protein kinase C inhibition by UCN-01 induces apoptosis in human glioma cells in a time-dependent fashion. J Neurooncol 1999;41:9-20.
12. Chang SM, Kuhn JG, Robins HI, et al. Phase II study of phenylacetate in patients with recurrent malignant glioma. J Clin Oncol 1999;17:984-90.
13. Curran WJ, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85:704-10.
14. Debinski W, Gibo DM, Hulet SW, et al. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res 1999;5:985-90.
15. Engelhard HH, Homer RJ, Duncan HA, et al. Inhibitory effects of phenylbutyrate on the proliferation, morphology, migration and invasiveness of malignant glioma cells. J Neurooncol 1998;37:97-108.
16. Fine HA, Dear KB, Loeffler JS, et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993;71:2585-97.
17. Fine HA, Loeffler JS, Kyritsis A, et al. A phase II trial of the anti-angiogenic agent thalidomide in patients with recurrent high-grade gliomas. Proc Am Soc Clin Oncol 1997;16:1372.abstract.
18. Ford JM, Stenning SP, Boote DJ, et al. A short fractionation radiotherapy treatment for poor prognosis patients with high grade glioma. Clin Oncol 1997;9:20-4.
19. Friedman HS, McLendon RE, Kerby T, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma. J Clin Oncol 1998;16:3851-7.
20. Glantz MJ, Chamberlain MC, Chang SM, et al. The role of paclitaxel in the treatment of primary and metastatic brain tumors. Semin Radiat Oncol 1999;9:Suppl 1:27-33.
21. Gross MW, Weber WA, Feldmann HJ, et al. The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. Int J Radiat Oncol Biol Phys 1998;41:989-95.
22. Grosu AL, Feldmann HJ, Albrecht C, et al. Three-dimensional irradiation planning in brain tumors. The advantages of the method and the clinical results. Strahlenther Onkol 1998;174:7-13.
23. Guderson S, Lote K, Hannisdal E. Prognostic factors for glioblastoma multiforme. Acta Oncol 1996;35:Suppl:123-7.
24. Gundersen S, Lote K, Watne K. A retrospective study of the value of chemotherapy as adjuvant therapy to surgery and radiotherapy in grade 3 and 4 gliomas. Eur J Cancer 1998;34:1565-9.
25. Guyatt GH, Sackett DL, Sinclair JC, et al. Users guide to the medical literature. IX. A method for grading health care recommendations. JAMA 1995;274:1880-4.
26. Haas-Kogan DA, Kogan SS, Yount G, et al. p53 function influences the effect of fractionated radiotherapy on glioblastoma tumors. Int J Radiat Oncol Biol Phys 1999;43:399-403.
27. Halperin EC, Herndon J, Schold SC, et al. A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. Int J Radiat Oncol Biol Phys 1996;34:793-802.
28. Hamada H, Tsuruo T. Functional role for the 170 to 180 kDa glycoprotein specific to drug resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 1986;83:7785-9.
29. Hideghety K, Sauerwein W, Haselsberger K, et al. Postoperative treatment of glioblastoma with BNCT at the Petten irradiation facility (EORTC protocol 11,961). Strahlenther Onkol 1999;175:Suppl 2:111-4.
30. Hiura T, Khalid H, Yamashita H, et al. Immunohistochemical analysis of metallothionein in astrocytic tumors in relation to tumor grade, proliferative potential, and survival. Cancer 1998;83:2361-9.
31. Hsu DW, Efird JT, Hedley-Whyte ET. Prognostic role of urokinase-type plasminogen activator in human gliomas. Am J Pathol 1995;147:114-23.
32. Huncharek M. Meta-analytic re-evaluation of misonidazole in the treatment of high grade astrocytoma. Anticancer Res 1998;18:1935-9.
33. Huncharek M, Muscat J, Geschwind JF. Multi-drug versus single agent chemotherapy for high grade astrocytoma: results of a meta-analysis. Anticancer Res 1998;18:4693-7.
34. Irish WD, Macdonald DR, Cairncross JG. To randomize or not to randomize: using a database to answer the question. Can J Neurol Sci 1997;24:307-312.
35. Iwadate Y, Fujimoto S, Tagawa M, et al. Association of p53 gene mutation with decreased chemosensitivity in human malignant glioma. Int J Cancer 1996;69:236-40.
36. James CD, Galanis E, Frederick L, et al. Tumor suppressor gene alterations in malignant gliomas: histopathological associations and prognostic evaluation. Int J Oncol 1999;15:547-53.
37. Kim JH, Kolozsvary A, Rogulski K, et al. Selective radiosensitization of 9L glioma in the brain transduced with double suicide fusion gene. Cancer J Sci Am 1998;4:364-9.
38. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993;362:841-4.
39. Knuepfer MM, Hernaiz-Driever P, Poppenborg H, et al. Valproic acid inhibits proliferation and changes expression of CD44 and CD56 of malignant glioma cells in vitro. Anticancer Res 1998;18:3585-90.
40. Lang O, Liebermeister E, Liesegang J, et al. Radiotherapy of glioblastoma multiforme: feasibility of increased fraction size and shortened overall treatment. Strahlenther Onkol 1998;174:629-32.
41. Laperriere NJ, Leung PM, McKenzie S, et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 1998;41:1005-11.
42. Levin VA, Silver P, Hannigan J, et al. Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 1990;18:321-4.
43. Loeffler JS, Alexander E, Shea WM, et al. Radiosurgery as part of the initial management of patients with malignant gliomas. J Clin Oncol 1992;10:1379-85.
44. Malkin M, Mason W, Leiberman F, et al. A phase I study of SU-101, a novel signal transduction inhibitor, in recurrent malignant glioma. Proc Am Soc Clin Oncol 1997;16:1371.abstract.
45. Matsukado K, Inamura T, Nakano S, et al. Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery 1996;39:125-33.
46. McDermott MW, Sneed PK, Gutin PH. Interstitial brachytherapy for malignant brain tumors. Semin Surg Oncol 1998;14:79-87.
47. Menei P, Venier MC, Gamelin E, et al. Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma. Cancer 1999;86:325-30.
48. Mitzumatsu S, Tamiya T, Ono Y, et al. Expression of cell cycle regulator p27Kip1 is correlated with survival of patients with astrocytoma. Clin Cancer Res 1999;5:551-7.
49. Morrison RS. Growth factor-mediated signaling pathways. In: Berger MS, Wilson CB, eds. The gliomas. Philadelphia: Saunders, 1999:52-63.
50. MRC Brain Tumor Working Party. Prognostic factors for high-grade malignant glioma: development of a prognostic index. J Neurooncol 1990;9:47-55.
51. Nelson DF, Curran WJ, Scott CB, et al. Hyperfractionated radiation therapy and bis-chlorethyl nitrosurea in the treatment of malignant glioma. Int J Radiat Oncol Biol Phys 1993;25:193-207.
52. Nieder C, Nestle U, Ketter R, et al. Hyperfractionated and accelerated-hyperfractionated radiotherapy for glioblastoma multiforme. Radiat Oncol Invest 1999;7:36-41.
53. Osoba D, Aaronson NK, Muller M, et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Quality of Life Res 1996;5:139-50.
54. Prados MD, Russo C. Chemotherapy of brain tumors. Semin Surg Oncol 1998;14:88-95.
55. Prados MD, Scott C, Curran WJ, et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol 1999;17:3389-95.
56. Price A, Shi Q, Morris D, et al. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin Cancer Res 1999;5:845-54.
57. Riva P, Franceschi G, Frattarelli M, et al. 1311 radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma. Acta Oncol 1999;38:351-9.
58. Ruan S, Okcu MF, Pong RC, et al. Attenuation of WAF1/Cip1 expression by an antisense adenovirus expression vector sensitizes glioblastoma cells to apoptosis induced by chemotherapeutic agents 1,3-bis(2-chloroethyl)1-nitrosourea and cisplatin. Clin Cancer Res 1999;5:197-202.
59. Samid D, Shack S, Myers CE. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by non-toxic pharmacological concentrations of phenylacetate. J Clin Invest 1993;91:2288-95.
60. Shafman TD, Loeffler JS. Novel radiation technologies for malignant gliomas. Curr Opin Oncol 1999;11:147-51.
61. Shapiro WR, Green S, Burger PC et al. A randomized trial of interstitial radiotherapy boost for the treatment of newly diagnosed malignant glioma: BTCG study 8701. Neurology (NY) 1994;44:Suppl 2:A263.abstract.
62. Shapiro WR, Green S, Burger PC, et al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 1992;76:772-81.
63. Shapiro WR, Green S, Burger PC, et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg 1989;71:1-9.
64. Shibamoto Y, Nishimura Y, Tsutsui K, et al. Comparison of accelerated hyperfractionated radiotherapy and conventional radiotherapy for supratentorial malignant glioma. Jpn J Clin Oncol 1997;27:31-6.
65. Shrieve DC, Alexander E, Black PM, et al. Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome. J Neurosurg 1999;90:72-7.
66. Simpson JR, Horton J, Scott CB, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive RTOG clinical trials. Int J Radiat Oncol Biol Phys 1993;26:239-44.
67. Sneed PK, Stauffer PR, McDermott MW, et al. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost ± hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1998; 40:287-95.
68. Snelling L, Miyamoto CT, Bender H, et al. Epidermal growth factor receptor 425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of high-grade astrocytomas. Hybridoma 1995;14:111-4.
69. Spear MA. Gene therapy of gliomas: receptor and transcriptional targeting. Anticancer Res 1998;18:3223-32.
70. Stemmer-Rachamimov AO, Louis DN. Histopathologic and immunohistochemical prognostic factors in malignant gliomas. Curr Opin Oncol 1997;9:230-4.
71. Tuvesson H, Gunnarsson PO, Seidegard J. Measurement and characterization of the denitrosation of tauromustine and related nitrosoureas by glutathione transferases in liver cytosol from various species. Carcinogenesis 1993;14:1143-7.
72. Van Kampen M, Engenhart-Cabillic R, Debus J, et al. Value of radiosurgery in first-line therapy of glioblastoma multiforme. Strahlenther Onkol 1998;174:187-92.
73. Von Bossanyi P, Diete S, Dietzmann K, et al. Immunohistochemical expression of P-glycoprotein and glutathione S-transferases in cerebral gliomas and response to chemotherapy. Acta Neuropathol 1997;94:605-11.
74. Walker MD, Strike TS, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979;5:1725-31.
75. Walker MD, Alexander E, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 1978;49:333-43.
76. Wei MX, Tamiya T, Chase M, et al. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther 1994;5:969-78.
77. Weitzner MA, Meyers CA, Gelke CK, et al. The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version in patients with primary brain tumors. Cancer 1995;75:1151-61.
78. Weller M, Frei K, Groscurth P, et al. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest 1994;94:954-64.
79. Werner-Wasik M, Scott CB, Nelson DF, et al. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Cancer 1996;77:1535-43.
80. Williams JA, Williams JR, Yuan X, et al. Protracted exposure radiosensitization of experimental human malignant glioma. Radiat Oncol Invest 1998;6:255-63.
81. Wolff J, Denecke J, Jurgens H. Dexamethasone induces partial resistance to cisplatinum in C6 glioma cells. Anticancer Res 1996;16:805-10.